Find Elacestrant manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 722533-56-4, Rad1901, Elacestrant [inn], Elacestrant [usan], Rad-1901, Er-306323
Molecular Formula
C30H38N2O2
Molecular Weight
458.6  g/mol
InChI Key
SIFNOOUKXBRGGB-AREMUKBSSA-N
FDA UNII
FM6A2627A8

Elacestrant
Elacestrant is an orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and estrogen-like activities. Upon oral administration of higher doses of elacestrant, this agent acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells. At lower doses of this agent, RAD1901 acts as a SERM and has estrogen-like effects in certain tissues, which can both reduce hot flashes and protect against bone loss. In addition, elacestrant is able to cross the blood-brain barrier (BBB).
1 2D Structure

Elacestrant

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(6R)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
2.1.2 InChI
InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1
2.1.3 InChI Key
SIFNOOUKXBRGGB-AREMUKBSSA-N
2.1.4 Canonical SMILES
CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)C3CCC4=C(C3)C=CC(=C4)O
2.1.5 Isomeric SMILES
CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)[C@@H]3CCC4=C(C3)C=CC(=C4)O
2.2 Other Identifiers
2.2.1 UNII
FM6A2627A8
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (6r)-6-(2-(ethyl((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol

2.3.2 Depositor-Supplied Synonyms

1. 722533-56-4

2. Rad1901

3. Elacestrant [inn]

4. Elacestrant [usan]

5. Rad-1901

6. Er-306323

7. Fm6a2627a8

8. (6r)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol

9. (6r)-6-{2-[ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol

10. (2r)-2-(2-(ethyl-((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxy-phenyl)tetralin-6-ol

11. (6r)-6-(2-(ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol

12. 2-naphthalenol, 6-(2-(ethyl((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydro-, (6r)-

13. Elacestrant (usan/inn)

14. Elacestrant [usan:inn]

15. Elacestrant [who-dd]

16. Schembl229431

17. Unii-fm6a2627a8

18. Chembl4297509

19. Bdbm349630

20. Dtxsid901045846

21. Glxc-26208

22. Ex-a5070

23. Us10208011, Compound Rad-

24. Mfcd30532693

25. Who 10247

26. Cs-6306

27. Db06374

28. Hy-19822

29. D11671

30. Q27278069

31. (r)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol

32. I0v

2.4 Create Date
2008-01-14
3 Chemical and Physical Properties
Molecular Weight 458.6 g/mol
Molecular Formula C30H38N2O2
XLogP36.3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count10
Exact Mass458.293328459 g/mol
Monoisotopic Mass458.293328459 g/mol
Topological Polar Surface Area44.7 Ų
Heavy Atom Count34
Formal Charge0
Complexity578
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in menopause and female hormonal deficiencies/abnormalities.


5 Pharmacology and Biochemistry
5.1 Mechanism of Action

RAD1901 is a novel selective estrogen receptor modulator(SERM). SERMs are small molecules that bind to and selectively modulate estrogen receptors. These molecules have the ability to stimulate or block estrogen's activity in different types of tissue, functioning as estrogen receptor agonists in some tissues and as estrogen receptor antagonists in others. RAD1901 has potential to reduce vasomotor symptoms, along with a simultaneous bone-protective effect, without stimulating breast or uterine tissues. RAD1901 is distinctive from other SERMs in its unique biological profile, combined with its significant ability to penetrate the blood-brain barrier, which enables RAD1901 to function as an estrogen agonist within the central nervous system and thereby relieve hot flashes.


API SUPPLIERS

read-more
read-more

01

Granules India Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Granules India

02

Seqens

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Compamed
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Flag France
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Seqens Company Banner

03

Moehs Iberica

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Moehs Iberica

04

Shandong Loncom Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Compamed
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shandong Loncom Pharmaceutical company banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Elacestrant

About the Company : Granules is a vertically integrated fast-growing Pharmaceutical company headquartered in Hyderabad with best-in-class facilities & a commitment to operational excellence, quality, ...

Granules is a vertically integrated fast-growing Pharmaceutical company headquartered in Hyderabad with best-in-class facilities & a commitment to operational excellence, quality, & customer service. The company is present in the manufacturing of the entire value chain – from APIs, Formulation Intermediates, & Formulations. Their products are being distributed to over 300+ customers with a global presence extending to over 80+ countries with offices across India, US & UK.
Granules India

02

Seqens

France
arrow
euroPLX 86 Munich
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Flag France
Digital Content Digital Content

Elacestrant

About the Company : Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling ...

Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling up and manufacturing drug substances from the pre-clinical phase to the commercial phase. It offers a large portfolio of APIs and proprietary products. Seqens also develops custom solutions and ingredients for the most demanding industries, such as healthcare, electronics and cosmetics. Its unique range of technologies enables it to manufacture complex molecules for small- and large-scale demands. It operates 24 industrial plants and 10 R&D centres across the globe.
Seqens Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content

Elacestrant

About the Company : Since its founding in 1962, MOEHS has produced Active Pharmaceutical Ingredients (APIs) for the international pharmaceutical industry. Thanks to a business history of more than 50 ...

Since its founding in 1962, MOEHS has produced Active Pharmaceutical Ingredients (APIs) for the international pharmaceutical industry. Thanks to a business history of more than 50 years, MOEHS has considerable technical experience in the production of these substances. At Moehs Group we have a large tradition and experience in the area of manufacturing of active pharmaceutical and veterinary ingredients, agrochemicals, nutraceutical, cosmetic, as well as fine chemistry in general, with high levels of quality and safety standards-GMP´s, ICH, approved by the FDA and TGA.
Moehs Iberica

04

arrow
euroPLX 86 Munich
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.

Flag China
Digital Content Digital Content

Elacestrant

About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...

Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development Zone, Shandong Province, Shandong Loncom has operational API pilot tests and production bases adhering to international standards. With 13 production lines dedicated to oral solid preparations, oral liquid preparations and API, it is actively expanding its preparation workshops for small-volume injections, soft capsules, eye drops, topical medicines and innovative drug R&D centres.
Shandong Loncom Pharmaceutical company banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Rupitasertib is an oral inhibitor of S6K and AKT1/AKT3 designed to block the PI3K/AKT/mTOR pathway, being investigated with elacestrant in ER+/HER2- advanced breast cancer with ESR1 mutation.


Lead Product(s): Rupitasertib,Elacestrant

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2024

blank

01

Evexta Bio

France
arrow
BioFlorida Conference
Not Confirmed

Evexta Bio

France
arrow
BioFlorida Conference
Not Confirmed

Details : Rupitasertib is an oral inhibitor of S6K and AKT1/AKT3 designed to block the PI3K/AKT/mTOR pathway, being investigated with elacestrant in ER+/HER2- advanced breast cancer with ESR1 mutation.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 22, 2024

blank

Details:

Under the agreement, SciClone will pursue the development and registration of Orserdu (elacestrant), a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, in China and commercialize Orserdu upon its regulatory approval in China.


Lead Product(s): Elacestrant

Therapeutic Area: Oncology Brand Name: Orserdu

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: SciClone Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement November 07, 2023

blank

02

Menarini

Italy
arrow
BioFlorida Conference
Not Confirmed

Menarini

Italy
arrow
BioFlorida Conference
Not Confirmed

Lead Product(s) : Elacestrant

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : SciClone Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Details : Under the agreement, SciClone will pursue the development and registration of Orserdu (elacestrant), a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, in China and commercialize Orserdu upon its regulatory a...

Brand Name : Orserdu

Molecule Type : Small molecule

Upfront Cash : Undisclosed

November 07, 2023

blank

Details:

Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.


Lead Product(s): Elacestrant

Therapeutic Area: Oncology Brand Name: Orserdu

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: European Organisation for Research and Treatment of Cancer

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 19, 2023

blank

03

Menarini

Italy
arrow
BioFlorida Conference
Not Confirmed

Menarini

Italy
arrow
BioFlorida Conference
Not Confirmed

Lead Product(s) : Elacestrant

Therapeutic Area : Oncology

Highest Development Status : Approved

Partner/Sponsor/Collaborator : European Organisation for Research and Treatment of Cancer

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an ...

Brand Name : Orserdu

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 19, 2023

blank

Details:

Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer.


Lead Product(s): Elacestrant

Therapeutic Area: Oncology Brand Name: Orserdu

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 20, 2023

blank

04

Menarini

Italy
arrow
BioFlorida Conference
Not Confirmed

Menarini

Italy
arrow
BioFlorida Conference
Not Confirmed

Details : Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic br...

Brand Name : Orserdu

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 20, 2023

blank

Details:

Under the agreement, DRI Healthcare gains a portion of Radius’s royalty and commercial milestone stream in Orserdu (elacestrant), a selective estrogen receptor degrader and the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or metastatic breast cancer.


Lead Product(s): Elacestrant

Therapeutic Area: Oncology Brand Name: Orserdu

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: DRI Healthcare

Deal Size: $140.0 million Upfront Cash: $130.0 million

Deal Type: Agreement August 14, 2023

blank

05

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : Under the agreement, DRI Healthcare gains a portion of Radius’s royalty and commercial milestone stream in Orserdu (elacestrant), a selective estrogen receptor degrader and the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or ...

Brand Name : Orserdu

Molecule Type : Small molecule

Upfront Cash : $130.0 million

August 14, 2023

blank

Details:

Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.


Lead Product(s): Elacestrant

Therapeutic Area: Oncology Brand Name: Orserdu

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2023

blank

06

Menarini

Italy
arrow
BioFlorida Conference
Not Confirmed

Menarini

Italy
arrow
BioFlorida Conference
Not Confirmed

Details : Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an ...

Brand Name : Orserdu

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 21, 2023

blank

Details:

Under the agreement, Eisai transfers all future economic rights for elacestrant, a selective estrogen receptor degrader, approved for the treatment for breast cancer in the United States, to DRI Healthcare Trust.


Lead Product(s): Elacestrant

Therapeutic Area: Oncology Brand Name: Elacestrant-Generic

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: DRI Healthcare

Deal Size: Undisclosed Upfront Cash: $85.0 million

Deal Type: Agreement June 29, 2023

blank

07

Eisai

Japan
arrow
BioFlorida Conference
Not Confirmed

Eisai

Japan
arrow
BioFlorida Conference
Not Confirmed

Details : Under the agreement, Eisai transfers all future economic rights for elacestrant, a selective estrogen receptor degrader, approved for the treatment for breast cancer in the United States, to DRI Healthcare Trust.

Brand Name : Elacestrant-Generic

Molecule Type : Small molecule

Upfront Cash : $85.0 million

June 29, 2023

blank

Details:

Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.


Lead Product(s): Elacestrant

Therapeutic Area: Oncology Brand Name: Orserdu

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 02, 2023

blank

08

Onco360

U.S.A
arrow
BioFlorida Conference
Not Confirmed

Onco360

U.S.A
arrow
BioFlorida Conference
Not Confirmed

Details : Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.

Brand Name : Orserdu

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 02, 2023

blank

Details:

Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.


Lead Product(s): Elacestrant

Therapeutic Area: Oncology Brand Name: Orserdu

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2023

blank

09

BioFlorida Conference
Not Confirmed
BioFlorida Conference
Not Confirmed

Details : Orserdu (elacestrant) is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). It inhibits 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway.

Brand Name : Orserdu

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 30, 2023

blank

Details:

RAD1901 (elacestrant) is an investigational selective estrogen receptor degrader (SERD). Preclinical studies indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer.


Lead Product(s): Elacestrant

Therapeutic Area: Oncology Brand Name: RAD1901

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 30, 2022

blank

10

Menarini

Italy
arrow
BioFlorida Conference
Not Confirmed

Menarini

Italy
arrow
BioFlorida Conference
Not Confirmed

Details : RAD1901 (elacestrant) is an investigational selective estrogen receptor degrader (SERD). Preclinical studies indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer.

Brand Name : RAD1901

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 30, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

read-more
read-more

01

LinkChem

China
BioFlorida Conference
Not Confirmed
arrow

LinkChem

China
BioFlorida Conference
Not Confirmed
arrow

CAS Number : 32263-70-0

End Use API : Elacestrant

About The Company : LinkChem is a leading China headquartered CMO | CRO provider within the pharmaceutical industry. Our core focus includes: custom synthesis, process development,...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

ELACESTRANT DIHYDROCHLORIDE

US Patent Number : 10420734

Drug Substance Claim :

Drug Product Claim :

Application Number : 217639

Patent Use Code : U-3524

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-10-10

blank

02

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

ELACESTRANT DIHYDROCHLORIDE

US Patent Number : 10745343

Drug Substance Claim :

Drug Product Claim :

Application Number : 217639

Patent Use Code : U-3523

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-01-05

blank

03

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

ELACESTRANT DIHYDROCHLORIDE

US Patent Number : 11779552

Drug Substance Claim :

Drug Product Claim :

Application Number : 217639

Patent Use Code : U-3524

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-10-10

blank

04

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

ELACESTRANT DIHYDROCHLORIDE

US Patent Number : 7612114

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217639

Patent Use Code : U-3523

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-08-18

blank

05

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

ELACESTRANT DIHYDROCHLORIDE

US Patent Number : 10385008

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217639

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-01-05

blank

06

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

ELACESTRANT DIHYDROCHLORIDE

US Patent Number : 7612114

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217639

Patent Use Code : U-3523

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-08-18

blank

07

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

ELACESTRANT DIHYDROCHLORIDE

US Patent Number : 10385008

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 217639

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2038-01-05

blank

08

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

ELACESTRANT DIHYDROCHLORIDE

US Patent Number : 10420734

Drug Substance Claim :

Drug Product Claim :

Application Number : 217639

Patent Use Code : U-3524

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-10-10

blank

09

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

ELACESTRANT DIHYDROCHLORIDE

US Patent Number : 10071066

Drug Substance Claim :

Drug Product Claim :

Application Number : 217639

Patent Use Code : U-3524

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-10-10

blank

10

arrow
American Pharma Summit
Not Confirmed
arrow
American Pharma Summit
Not Confirmed

ELACESTRANT DIHYDROCHLORIDE

US Patent Number : 11779552

Drug Substance Claim :

Drug Product Claim :

Application Number : 217639

Patent Use Code : U-3524

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2034-10-10

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty